$680 Million is the total value of Aquilo Capital Management, LLC's 14 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 14.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| XBI | New | SPDR S&P BIOTECH ETF TRcall | $179,760,000 | – | 2,000,000 | +100.0% | 26.42% | – |
| SPY | Sell | SPDR S&P 500 ETF TRput | $158,074,000 | -66.7% | 350,000 | -65.0% | 23.23% | -56.9% |
| BPMC | Buy | BLUEPRINT MEDICINES CORP | $49,925,000 | -27.8% | 781,539 | +21.1% | 7.34% | -6.4% |
| ARWR | Buy | ARROWHEAD PHARMACEUTICALS IN | $48,172,000 | +3.7% | 1,047,440 | +49.5% | 7.08% | +34.4% |
| ARVN | Buy | ARVINAS INC | $46,790,000 | +1.1% | 695,247 | +23.4% | 6.88% | +31.0% |
| SPRO | Buy | SPERO THERAPEUTICS INC | $45,949,000 | -42.2% | 5,281,504 | +6.4% | 6.75% | -25.1% |
| RGNX | Buy | REGENXBIO INC | $37,129,000 | +12.0% | 1,118,684 | +10.4% | 5.46% | +45.2% |
| MRUS | Buy | MERUS N V | $33,355,000 | +17.0% | 1,261,534 | +40.7% | 4.90% | +51.6% |
| FDMT | Buy | 4D MOLECULAR THERAPEUTICS IN | $26,543,000 | -19.9% | 1,755,506 | +16.3% | 3.90% | +3.8% |
| QURE | Buy | UNIQURE NV | $16,290,000 | +16.1% | 901,490 | +33.3% | 2.39% | +50.5% |
| AMYT | AMRYT PHARMA PLCsponsored ads | $13,563,000 | -23.4% | 1,640,000 | 0.0% | 1.99% | -0.8% | |
| PIRS | Buy | PIERIS PHARMACEUTICALS INC | $11,238,000 | -7.0% | 3,708,882 | +16.0% | 1.65% | +20.6% |
| ARGX | Buy | ARGENX SEsponsored adr | $7,567,000 | -2.7% | 24,000 | +8.1% | 1.11% | +26.1% |
| GMAB | Buy | GENMAB A/Ssponsored ads | $6,060,000 | +20.1% | 167,500 | +31.4% | 0.89% | +55.8% |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -3,155,082 | -100.0% | -1.58% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| PIERIS PHARMACEUTICALS INC | 20 | Q3 2023 | 7.1% |
| ARROWHEAD PHARMACEUTICALS INC | 18 | Q3 2023 | 22.1% |
| UNIQURE NV | 18 | Q1 2023 | 10.8% |
| SPERO THERAPEUTICS INC | 16 | Q3 2022 | 15.8% |
| REGENXBIO INC | 16 | Q3 2023 | 12.6% |
| BLUEPRINT MEDICINES CORP | 15 | Q3 2023 | 17.3% |
| ARGENX SE | 15 | Q3 2023 | 3.7% |
| SPDR S&P BIOTECH ETF TR | 14 | Q4 2022 | 52.1% |
| MERUS N V | 14 | Q3 2023 | 13.0% |
| GENMAB A/S | 13 | Q3 2023 | 3.9% |
View Aquilo Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Spero Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Merus N.V. | February 14, 2020 | 814,505 | 2.8% |
| SYNLOGIC, INC.Sold out | February 14, 2020 | 0 | 0.0% |
View Aquilo Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-03-18 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
View Aquilo Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.